Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial

Launched by UNIVERSITY OF PALERMO · May 14, 2025

Keywords

ClinConnect Summary

The AURA Trial is a clinical study designed to help women with adenomyosis—a condition that can cause heavy periods, pelvic pain, and challenges with getting pregnant. The trial aims to see if adding a medication called letrozole to standard fertility treatment improves the chances of a successful pregnancy for these women. Participants will be women aged 18 and older who have been diagnosed with adenomyosis using a special ultrasound technique.

During the trial, eligible women will receive either monthly injections of a hormone-suppressing medication or the same injections along with daily letrozole tablets for 90 days. After this treatment, all women will proceed with the usual steps for assisted reproductive technology (ART), such as embryo transfer. Throughout the study, participants will receive comprehensive evaluations to monitor their health and progress. By participating in this trial, women not only gain access to innovative treatments but also help researchers learn more about effective ways to support women facing infertility due to adenomyosis. If you’re interested in participating or want more information, you can contact the Instituto Bernebeu Assisted Reproduction Center for guidance.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - Infertile patients affected by adenomyosis diagnosed by 2D-3D transvaginal ultrasound according to revised Morphological Uterus Sonographic Assessment consensus.
• Exclusion Criteria:
• • concomitant uterine fibroids,
• • Müllerian malformations,
• • endometrial pathology,
• • thin endometrium,
• • hydrosalpinx,
• • mucometra,
• • previous surgery except for previous cesarean section,
• • coagulation disorders,
• • untreated endocrinopathies,
• • severe seminal pathologies,
• • double ET,
• • ET different from the first one after adenomyosis treatment.